Asymmetric dimethylarginine levels in allergic rhinitis and nasal polyposis

Authors: MEHMET TOSUN, TAYFUN APUHAN

Abstract: Asymmetric dimethylarginine (ADMA) is the major endogenous inhibitor of nitric oxide synthase. We aimed to investigate the ADMA levels in allergic rhinitis (AR) and nasal polyposis (NP). Materials and methods: A total of 29 AR patients, 21 NP patients, and 30 healthy subjects to be used as a control group were enrolled in the study. ADMA was measured in the AR, NP, and control groups with enzyme-linked immunosorbent assay. Any patients or control subjects with coronary artery disease, renal failure, diabetes mellitus, or hypertension were excluded from the study. Results: The mean ADMA serum concentration was 0.52 ± 0.08 µmol/L in the AR group, 0.62 ± 0.10 µmol/L in the NP group, and 0.67 ± 0.09 µmol/L in the control group. The ADMA serum concentration in the AR group was significantly lower than in the control group (P < 0.001). Considered together, the NP and AR groups had ADMA levels that were significantly lower than in the control group (P < 0.001). Conclusion: In the present study, lower ADMA levels were found in the AR and NP groups.

Keywords: Asymmetric dimethylarginine, allergic rhinitis, nasal polyposis

Full Text: PDF